High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The memorial Sloan-Kettering experience (1988-1999)

International Journal of Cancer

Volumn 83, Issue 6, 1999, Pages 834-838

  Morris, Michael J ^a   Bosl, George J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER FAILURE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW TRANSPLANTATION; CANCER CARE FACILITIES; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; GERMINOMA; HUMANS; MALE; NEW YORK CITY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TESTICULAR NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE;

EID: 0032756459     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991210)83:6<834::AID-IJC25>3.0.CO;2-I     Document Type: Conference Paper

References (30)

1. BEYER, J., SCHWELLA, N., ZINGSEM, J., STROHSCHEER, I., SCHWANER, I., OETTLE, H., SERKE, S., HUHN, D. and STIEGER, W., Hematopoietic rescue after high-dose chemotherapy using autolugous peripheral-blood progenitor cells or bone marrow. A randomized comparison. J. clin. Oncol., 13, 1328-1335 (1995).
2. BOSL, G.J., GELLER, N.L. and BAJORIN, D., Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Semin. Oncol. 15, 339-344 (1988).
3. BOSL, G.J., GELLER, N.L., CIRRINCIONE, C., VOGELZANG, N.J., KENNEDY, B.J., WHITMORE, W.F., JR., VUGRIN, D., SCHER, H., NISSELBAUM, J. and GOLBEY, R.B., Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res., 43, 3403-3407 (1983).
4. BOSL, G.J., GELLER, N.L., VOGELZANG, N.J., CAREY, R., AUMAN, J., WHITMORE, W.F., HERR, H., MORSE, M., SOGANI, P. and CHAN, E., Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J. clin.Oncol., 5, 436-440 (1987).
5. BOSL, G.J., GLUCKMAN, R., GELLER, N.L., GOLBEY, R.B., WHITMORE, W.F., HERR, H., SOGANI, P., MORSE, M., MARTINI, N., BAINS, M. and MCCORMACK, P., VAB-6: an effective chemotherapy regimen for patients with germ cell tumors. J. clin. Oncol., 4, 1493-1499 (1986).
6. BROUN, E.R., NICHOLS, C.R., KNEEBONE, P., WILLIAMS, S.D., LOEHRER, P.J., EINHORN, L.H. and TRICOT, G.J., Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med., 117, 124-128 (1992).
7. BUCKNER, C.D., CLIFT, R.A., FEFER, A., FUNK, D.D., GLUCKSBEKG, H., NEIMAN, P.E., PAULSEN, A., STORB, R. and THOMAS, E.D., High dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother. Rep., 58, 709-714 (1974).
8. CHEVREAU, C., DROZ, J.P., PICO, J.L., BIRON, P., KERBRAT, P., CURE, H., HERON, J.F., CHEVALLIER, B., FARGEOT, P., KRAMER, A. and BOUZY, J., Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Europ. Urol., 23, 213-217 (1993).
9. DROZ, J.P., KRAMAR, A. and PICO, J.L., Prediction of long term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non seminomatous germ cell tumors. Europ. J. Cancer, 29A, 818-821 (1993).
10. EINHORN, L.H., WEATHERS, T., LOEHRER, P. and NICHOLS, C., Second line chemotherapy with virblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin, VP-16, and bleomycin (PVP16B) in disseminated germ cell tumors (GCT): long term follow-up [Abstract]. Proc. Amer. Soc. clin. Oncol., 11, 599 (1992).
11. GERL, A., LAMERZ, R., CLEMM, C., MANN, K., HARTENSTEIN, R. and WILMANNS, W., Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin. Cancer Res., 2, 1565-1570 (1996).
12. INTERNATIONAL GERM CELL CANCER COLLABORATIVE GROUP, International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J. clin. Oncol., 15, 594-603 (1997).
13. MOTZER, R., MAZUMDAR, M., BOSL, G.J., BAJORIN, D.F., AMSTERDAM, A. and VLAMIS, V., High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. clin. Oncol., 14, 1305-1310 (1996).
14. MOTZER, R.J., BAJORIN, D.F. and BOSL, G.J., "Poor-risk" germ cell tumors: current progress and future directions. Semin. Oncol., 19, 206-214 (1992).
15. MOTZER, R.J., BAJORIN, D.F., VLAMIS, V., WEISEN, S. and BOSL, G.J., Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Semin. Oncol., 19, 8-12 (1992).
16. MOTZER, R.J. and BOSL, G.J., High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J. nat. Cancer Inst., 84, 1703-1709 (1992).
17. MOTZER, R.J., COOPER, K., GELLER, N.L., BAJORIN, D.F., DMITROVSKY, E., HERR, H., MORSE, M., FAIR, W., SOGANI, P., RUSSO, P. and BOSL, J., The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer, 66, 2476-2481 (1990).
18. MOTZER, R.J., GELLER, N.L., TAN, C.C., HERR, H., MORSE, M., FAIR, W., SCHEINFELD, J.S., RUSSO, P. and BOSL, G.J., Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer, 67, 1305-1310 (1991).
19. MOTZER, R.J., GULATI, S.C., TONG, W.P., MENENDEZ-BOTET, C., LYN, P., MAZUMDAR, M., VLAMIS, V., LIN, S. and BOSL, G.J., Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res., 53, 3730-3735 (1993a).
20. MOTZER, R.J., MAZUMDAR, M., BOSL, G.J., BAJORIN, D.F., AMSTERDAM, A. and VLAMIS, V., High dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. clin. Oncol., 14, 1098-1105 (1996).
21. MOTZER, R.J., MAZUMDAR, M., BAJORIN, D.F., BOSL, G.J., LYN, P. and VLAMIS, V., High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. clin. Oncol., 15, 2546-2552 (1997).
22. MOTZER, R.J., MAZUMDAR, M., GULATI, S.C., BAJORIN, D.F. VLAMIS, V. and BOSL, G.J., Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. nat. Cancer Inst., 85, 1828-1835 (1993b).
23. MURPHY, B.A., MOTZER, R.J., MAZUMDAR, M., VLAMIS, V., NISSELBAUM, J., BAJORIN, D. and BOSL, G.J., Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer, 73, 2520-2526 (1994).
24. NICHOLS, C.R., CATALANO, P.J., CRAWFORD, E.D., VOGELZANG, N.J., EINHORN, L.H. and LOEHRER, P.J., Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Leukemia Group B study. J. clin. OncoL 16, 1287-1293 (1998).
25. NICHOLS, C.R. AND 13 OTHERS, Dose intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. clin. Oncol., 7, 932-939 (1989).
26. NICHOLS, C.R., WILLIAMS, S.D., LOEHRER, P.J., GRECO, F.A., CRAWFORD, E.D., WEETLAUFER, J., MILLER, M.E., BARTOLUCCI, A., SCHACTER, L. and EINHORN, L.H., Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol., 9, 1163-1172 (1991).
27. NUMUNAITIS, J., RABINOWE, S. and SINGER, J., Recombinant granulocytemacrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med., 324, 1773-1778 (1991).
28. STEVENS, M.J., NORMAN, A.R., DEARNALEY, D.P. and HORWITCH, A., Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J. clin. Oncol., 13, 87-92 (1995).
29. TONER, G.C., GELLER, N.L., TSCAN, C., NISSELBAUM, J. and BOSL, G.J., Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res., 50, 5904-5910 (1990).
30. WILLIAMS, S.D., BIRCH, R., EINHORN, L.H., IRWIN, L., GRECO, F.A. and LOEHRER, P.J., Treatment of disseminated germ cell tumors with cisplatinum, bleomycin and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435-1440 (1987).